Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium

  • Girolamo Pelaia | pelaia@unicz.it Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Graecia” of Catanzaro, Campus Universitario “S. Venuta”, Catanzaro, Italy.
  • Rosario Maselli Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Graecia” of Catanzaro, Campus Universitario “S. Venuta”, Catanzaro, Italy.
  • Luca Gallelli Department of Health Science, Section of Pharmacology, University “Magna Graecia” of Catanzaro, Catanzaro, Italy.

Abstract

Chronic obstructive pulmonary disease (COPD) is a widespread respiratory disorder, usually characterized by progressive and poorly reversible airflow limitation. Inhaled long-acting bronchodilators, namely LABA (long-acting β2-adrenergic agonists) and LAMA (long-acting muscarinic receptor antagonists) are the mainstay of COPD treatment. Because the symptoms of many patients with COPD do not satisfactorily improve by using a single, either LABA or LAMA bronchodilator, the synergism of action resulting from the combination of the different bronchodilating mechanisms activated by LABA and LAMA, respectively, can significantly contribute to a better disease control. Based on these clinical and pharmacological considerations, several LABA/LAMA fixed-dose combinations have been developed and experimentally evaluated. Within such a context, the drug co-formulation containing indacaterol and glycopyrronium is probably the LABA/LAMA association which has been most extensively studied during the last few years.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-12-08
Info
Issue
Section
Reviews
Keywords:
Co-formulation, Dual bronchodilation, Glycopyrronium, Indacaterol, LABA, LAMA, Synergism, QVA149
Statistics
  • Abstract views: 78

  • PDF: 73
  • HTML: 9
How to Cite
Pelaia, G., Maselli, R., & Gallelli, L. (2014). Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. Multidisciplinary Respiratory Medicine, 9(1). https://doi.org/10.4081/mrm.2014.399